The Pharmaceutical Journal
Vol 269 No 7209 p151
3 August 2002

This article
Reprint
Photocopy

News summary

New drug regimen effective in HIV

A drug regimen containing a non-peptide protease inhibitor, tipranavir, has been shown to reduce HIV-1 levels in patients who have previously received multiple protease inhibitor regimens, according to new phase IIb data.

After 48 weeks of treatment, virus from patients who had up to 20 protease inhibitor-resistant mutations at baseline were susceptible to tipranavir.

Tipranavir is being developed by Boehringer Ingelheim. Data were presented at the 11th International HIV Drug Resistance Workshop, held in Seville last month.